Skin barrier dysfunction, a defining feature of atopic dermatitis (AD), arises from multiple
interacting systems. In AD, skin inflammation is caused by host–environment interactions …

Atopic dermatitis (AD), the most common chronic inflammatory skin disease, is driven by
both terminal keratinocyte differentiation defects and strong type 2 immune responses. In …

BACKGROUND: Atopic dermatitis (AD) is a common disease with an increasing prevalence.
The primary pathogenesis of the disease is still elusive, resulting in the lack of specific …

Atopic dermatitis (AD), a chronic relapsing inflammatory skin disease, is increasing in
prevalence around the world. Intensive research is ongoing to understand the mechanisms …

Introduction: Dupilumab is a new treatment option for patients with moderate-to-severe
atopic dermatitis. It blocks IL-4/IL13-signaling and thereby inhibits receptor signaling …

We recently showed that dendritic cells (DCs) activated by thymic stromal lymphopoietin
(TSLP) prime naive CD4+ T cells to differentiate into T helper type 2 (Th2) cells that …

Atopic dermatitis (AD), a common chronic inflammatory skin disease, is characterized by
inflammatory cell skin infiltration. The JAK-STAT pathway has been shown to play an …

The recent interest and elucidation of the JAK/STAT signaling pathway created new targets
for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical …

Background Several lines of evidence support a genetic component to alopecia areata (AA),
including differences in patients based on severity of AA, associated diseases and family …

abstract Interleukin (IL)-4 and IL-13, signature type 2 cytokines, exert their actions by binding
to two types of receptors sharing the IL-4R a chain (IL-4Ra). Since IL-4 and IL-13 play …